PF-06821497

DB14799InvestigationalSmall molecule

PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).

Formula / weight: C₂₂H₂₄Cl₂N₂O₅ · 467.34 g/mol (avg)
Also known as: Mevrometostat
Code names: PF-06821497

Resolves to

Compound

UNIIS4L4MM20B6CAS1844849-10-0ChEMBLCHEMBL4080228

Structure

InChIKeyRXCVUHMIWHRLDF-HXUWFJFHSA-NSMILESCO[C@H](C1COC1)C1=C(Cl)C2=C(CCN(CC3=C(OC)C=C(C)NC3=O)C2=O)C(Cl)=C1

Targets

Q15910EZH2

What you can answer from here — as of July 15, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with PF-06821497, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account